... Bibliografía tumores partes blandas ...

Tumores Benignos de partes blandas

  1. Ackerman, L. V.: Extra-osseous localized non-neoplastic bone and cartilage formation (so-called myositis ossificans). Clinical and pathological confusion with malignant neoplasms. J. Bone and Joint Surg., 40-A: 279-298, April 1958. 
  2. Barber, K. W., Jr.; Bianco, A. J., Jr.; Soule, E. H.; and MacCarty, C. S.: Benign extraneural soft-tissue tumors of the extremities causing compression of nerves. J. Bone and Joint Surg., 44-A: 98-104, Jan. 1962.
  3. Beham, A., and Fletcher, C. D.: Intramuscular angioma: a clinicopathological analysis of 74 cases. Histopathology, 18: 53-59, 1991. 
  4. Buetow, P. C.; Kransdorf, M. J.; Moser, R. P., Jr.; Jelinek, J. S.; and Berrey, B. H.: Radiologic appearance of intramuscular hemangioma with emphasis on MR imaging. AJR: Am. J. Roentgenol., 154: 563-567, 1990. 
  5. Cohen, E. K.; Kressel, H. Y.; Perosio, T.; Burk, D. L., Jr.; Dalinka, M. K.; Kanal, E.; Schiebler, M. L.; and Fallon, M. D.: MR imaging of soft-tissue hemangiomas: correlation with pathologic findings. AJR: Am. J. Roentgenol., 150: 1079-1081, 1988. 
  6. Demas, B. E.; Heelan, R. T.; Lane, J.; Marcove, R.; Hajdu, S.; and Brennan, M. F.: Soft-tissue sarcomas of the extremities: comparison of MR and CT in determining the extent of disease. AJR: Am. J. Roentgenol., 150: 615-620, 1988. 
  7. Ehman, R. L.; Berquist, T. H.; and McLeod, R. A.: MR imaging of the musculoskeletal system: a five-year appraisal. Radiology, 166: 313-320, 1988.
  8. Enneking, W. F.: Musculoskeletal Tumor Surgery. Vol. 1, pp. 14-19. New York, Churchill Livingstone, 1983. 
  9. Enneking, W. F.; Spanier, S. S.; and Goodman, M. A.: A system for the surgical staging of musculoskeletal sarcoma. Clin. Orthop., 153: 106-120, 1980.
  10. Enzinger, F. M., and Harvey, D. A.: Spindle cell lipoma. Cancer, 36: 1852-1859, 1975. 
  11. Enzinger, F. M., and Weiss, S. W.: Soft Tissue Tumors, pp. 1, 5-7. St. Louis, C. V. Mosby, 1983. 
  12. Evans, H. L.; Soule, E. H.; and Winkelmann, R. K.: Atypical lipoma, atypical intramuscular lipoma, and well differentiated 
  13. Glowacki, J., and Mulliken, J. B.: Mast cells in hemangiomas and vascular malformations. Pediatrics, 70: 48-51, 1982. 
  14. Kransdorf, M. J.; Jelinek, J. S.; Moser, R. P., Jr.; Utz, J. A.; Brower, A. C.; Hudson, T. M.; and Berrey, B. H.: Soft-tissue masses: diagnosis using MR imaging. AJR: Am. J. Roentgenol., 153: 541-547, 1989. 
  15. Mankin, H. J.; Lange, T. A.; and Spanier, S. S.: The hazards of biopsy in patients with malignant primary bone and soft-tissue tumors. J. Bone and Joint Surg., 64-A: 1121-1127, Oct. 1982. 
  16. Petasnick, J. P.; Turner, D. A.; Charters, J. R.; Gitelis, S.; and Zacharias, C. E.: Soft-tissue masses of the locomotor system: comparison of MR imaging with CT. Radiology, 160: 125-133, 1986. 
  17. Pettersson, H.; Gillespy, T., III; Hamlin, D. J.; Enneking, W. F.; Springfield, D. S.; Andrew, E. R.; Spanier, S.; and Slone, R.: Primary musculoskeletal tumors: examination with MR imaging compared with conventional modalities. Radiology, 164: 237-241, 1987.   
  18. retroperitoneal liposarcoma: a reappraisal of 30 cases formerly classified as well differentiated liposarcoma. Cancer, 43: 574-584, 1979. 
  19. Richardson, M. L.; Kilcoyne, R. F.; Gillespy, T., III; Helms, C. A.; and Genant, H. K.: Magnetic resonance imaging of musculoskeletal neoplasms. Radiol. Clin. North America, 24: 259-267, 1986. 
  20. Rogalski, R.; Hensinger, R.; and Loder, R.: Vascular abnormalities of the extremities: clinical findings and management. J. Pediat. Orthop., 13: 9-14, 1993. 
  21. Shmookler, B. M., and Enzinger, F. M.: Pleomorphic lipoma: a benign tumor simulating liposarcoma. A clinicopathologic analysis of 48 cases. Cancer, 47: 126-133, 1981. 
  22. Sim, F. H.; Frassica, F. J.; and Frassica, D. A.: Soft-tissue tumors: diagnosis, evaluation, and management. J. Am. Acad. Orthop. Surg., 2: 202-211, 1994.
  23. Simon, M. A.: Current concepts review. Biopsy of musculoskeletal tumors. J. Bone and Joint Surg., 64-A: 1253-1257, Oct. 1982. 
  24. Sundaram, M., and McLeod, R. A.: MR imaging of tumor and tumorlike lesions of bone and soft tissue. AJR: Am. J. Roentgenol., 155: 817-824, 1990. 
  25. Yakes, W. F.; Haas, D. K.; Parker, S. H.; Gibson, M. D.; Hooper, K. D.; Mulligan, J. S.; Pevsner, P. H.; Johns, J. C., Jr.; and Carter, T. E.: Symptomatic vascular malformations: ethanol embolotherapy. Radiology, 170: 1059-1066, 1989.

Sarcomas de partes blandas 

  1. Aisen, AM, Martel, W, Braunstein, EM, et al. MRI and CT evaluation of primary bone and soft-tissue tumors. AJR Am J Roentgenol 1986; 146:749.
  2. Alvegard, TA, Berg, NE. Cellular DNA contents and prognosis of high-grade soft tissue sarcoma. J Clin Oncol 1990; 8:538.
  3. Alvegard, TA, Berg, NO. Histopathology peer review of high grade soft tissue sarcoma: The Scandinavian Sarcoma Group experience. J Clin Oncol 1989; 7:1845.
  4. Antman K, Crowley J, Balcerzak SP, et al.: An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. Journal of Clinical Oncology 11(7): 1276-1285, 1993.
  5. Blanke CD, von Mehren M, Joensuu H, et al.: Evaluation of the safety and efficacy of an oral molecularly-targeted therapy, STI157, in patients (pts) with unresectable or metastatic gastrointestinal stromal tumors (GISTs) expressing c-kit (CD117). Proceedings of the American Society of Clinical Oncology 20: A-1, 1a, 2001.
  6. Blom, R, Guerrieri, C, Stål, O, et al. Leiomyosarcoma of the uterus: A clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 49 cases. Gynecol Oncol 1998; 68:54.
  7. Borden EC, Amato DA, Rosenbaum C, et al.: Randomized comparison of three Adriamycin regimens for metastatic soft tissue sarcomas. Journal of Clinical Oncology 5(6): 840-850, 1987.
  8. Brennan MF, Casper ES, Harrison LB: Soft tissue sarcoma. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds.: Cancer: Principles and Practice of Oncology. Philadelphia, Pa: Lippincott-Raven Publishers, 5th ed., 1997, pp 1738-1788.
  9. Cancer statistics 2000. CA Cancer J Clin 2000; 50:12.
  10. Casson AG, Putman JB, Natarajan G, et al.: Five-year survival after pulmonary metastasectomy for adult soft tissue sarcoma. Cancer 69(3): 662-668, 1992.
  11. Cheng, EY, Springfield, DS, Mankin, HJ. Frequent incidence of extrapulmonary sites of initial metastasis in patients with liposarcoma. Cancer 1995; 75:1120.
  12. Clark, J, Rocques, PJ, Crew, AJ, et al. Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma. Nat Genet 1994; 7:502.
  13. Coindre, JM, Trojani, M. Reproducibility of a histopathologic grading system for adult soft tissue sarcoma. Cancer 1986; 58:306.
  14. Coindre, JM. Pathology and grading of soft tissue sarcomas. Cancer Treat Res 1993; 67:1.
  15. Collin CF, Friedrich C, Godbold J, et al.: Prognostic factors for local recurrence and survival in patients with localized extremity soft-tissue sarcoma. Seminars in Surgical Oncology 4(1): 30-37, 1988.
  16. Collin, F, Chassevent, A, Bonichon, F, et al. Flow cytometric DNA content analysis of 185 soft tissue neoplasms indicates that S-phase fraction is a prognostic factor for sarcomas. Cancer 1997; 79:2371.
  17. Costa, J, Wesley, RA, Glatstein, E, Rosenberg, SA. The grading of soft tissue sarcomas. Results of a clinicohistopathologic correlation in a series of 163 cases. Cancer 1984; 53:530.
  18. Deenik, W, Mooi, WJ, Rutgers, EJ, et al. Clear cell sarcoma (malignant melanoma) of soft parts: A clinicopathologic study of 30 cases. Cancer 1999; 86:969.
  19. Demas, BE, Heelan, RT, Lane, J, et al. Soft-tissue sarcomas of the extremities: Comparison of MR and CT in determining the extent of disease. AJR Am J Roentgenol 1988; 150:615.
  20. Dreinhofer, KE, Akerman, M, Willen, H, et al. Proliferating cell nuclear antigen (PCNA) in high-grade malignant fibrous histiocytoma: Prognostic value in 48 patients. Int J Cancer 1994; 59:379.
  21. Dubben, HH, Thames, HD, Beck-Bornholdt, HP. Tumor volume: a basic and specific response predictor in radiotherapy. Radiother Oncol 1998; 47:167.
  22. Enneking, WF, Spanier, SS, Goodman, MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop 1980; 153:106.
  23. Enzinger, FM, Weiss, SW. Soft Tissue Tumors. CV Mosby, St. Louis/Toronto/London, 1983.
  24. Enzinger, FM. Weiss, SW. Soft Tissue Tumors. CV Mosby Co, St. Louis, Toronto, London, 1983; p 787
  25. Fish FS: Soft tissue sarcomas in dermatology. Dermatologic Surgery 22(3): 268-273, 1996.
  26. Frascella, E, Toffolatti, L, Rosolen, A. Normal and rearranged PAX3 expression in human rhabdomyosarcoma. Cancer Genet cytogenet 1998; 102:104.
  27. Garcia, RL, Coltrera, MD, Gown, AM. Analysis of proliferative grade using anti-PCNA/cyclin monoclonal antibodies in fixed, embedded tissues. Comparison with flow cytometric analysis. Am J Pathol 1989; 134:733.
  28. Gaynor, JJ, Tan, CC, Casper, ES, et al. Refinement of clinicopathologic staging for localized soft tissue sarcoma of the extremity: A study of 423 adults. J Clin Oncol 1992; 10:1317.
  29. Geer RJ, Woodruff J, Casper ES, et al.: Management of small soft-tissue sarcoma of the extremity in adults. Archives of Surgery 127(11): 1285-1289, 1992.
  30. Guillou, L, Coindre, JM, Bonichon, F, et al. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol 1997; 15:350.
  31. Gustafson, P, Dreinhofer, KE, Rydholm, A. Soft tissue sarcoma should be treated at a tumor center. A comparison of quality of surgery in 375 patients. Acta Orthop Scand 1994; 65:47.
  32. Gustafson, P, Ferno, M, Akerman, M, et al. Flow cytometric S-phase fraction in soft-tissue sarcoma: Prognostic importance analysed in 160 patients. Br J Cancer 1997; 75:94.
  33. Gustafson, P, Herrlin, K, Biling, L, et al. Necrosis observed on CT enhancement is of prognostic value in soft tissue sarcoma. Acta Radiol 1992; 33:474.
  34. Herman D Suit, MD, DPhil, Overview of Soft Tissue Sarcoma . Editor — Bone and Soft Tissue Tumors, Professor of Radiation Oncology, Harvard Medical School; Ira Spiro, MD, PhD, Assistant Professor of Oncology, Harvard Medical School; Thomas F DeLaney, MD, Editor — Bone and Soft Tissue Tumors, Lecturer in Radiation Oncology, Harvard Medical School.
  35. Heslin MJ, Lewis JJ, Nadler E, et al.: Prognostic factors associated with long-term survival for retroperitoneal sarcoma: implications for management. Journal of Clinical Oncology 15(8): 2832-2839, 1997.
  36. Heslin, MJ, Cordon-Cardo, C, Lewis, JJ, et al. Ki-67 detected by MIB-1 predicts distant metastasis and tumor mortality in primary, high grade extremity soft tissue sarcoma. Cancer 1998; 83:490.
  37. Heslin, MJ, Lewis, JJ, Woodruff, JM, Brennan, MF. Core needle biopsy for diagnosis of extremity soft tissue sarcoma. Ann Surg Oncol 1997; 4:425.
  38. Hisaoka, M, Tsuji, S, Morimitsu, Y, et al. Detection of TLS/FUS-CHOP fusion transcripts in myxoid and round cell liposarcomas by nested reverse transcription-polymerase chain reaction using archival paraffin-embedded tissues. Diagn Mol Pathol 1998; 7:96.
  39. Jaques DP, Coit DG, Hajdu SI, et al.: Management of primary and recurrent soft-tissue sarcoma of the retroperitoneum. Annals of Surgery 212(1): 51-59, 1990.
  40. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al.: Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. New England Journal of Medicine 344(14): 1052-1056, 2001.
  41. Kanoe, H, Nakayama, T, Hosaka, T, et al. Characteristics of genomic breakpoints in TLS-CHOP translocations in liposarcomas suggest the involvement of Translin and topoisomerase II in the process of translocation. Oncogene 1999; 18:721.
  42. Kawai, A, Woodruff, J, Healey, JH, et al. SVT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma. N Engl J Med 1998; 338:153.
  43. Khan, J, Bittner, ML, Saal, LH, et al. cDNA microarrays detect activation of a myogenic transcription program by the PAX3-FKHR fusion oncogene. Proc Natl Acad Sci U S A 1999; 96:13264.
  44. Koscielny, S, Tubiana, M, Le, MG, et al. Breast cancer: relationship between the size of the primary tumour and the probability of metastatic dissemination. Br J Cancer 1984; 49:709.
  45. Kreicbergs, A, Tribukait, B, Willems, J, Bauer, HC. DNA flow analysis of soft tissue tumors. Cancer 1987; 59:128.
  46. Lawrence, W Jr, Donegan, WL, Natarajan, N, et al. Adult soft tissue sarcomas. A pattern of care survey of the American College of Surgeons. Ann Surg 1987; 205:349.
  47. Le Doussal V, Coindre JM, Leroux A, et al.: Prognostic factors for patients with localized primary malignant fibrous histiocytoma. Cancer 77(9): 1823-1830, 1996.
  48. Le QT, Fu KK, Kroll S, et al.: Prognostic factors in adult soft-tissue sarcomas of the head and neck. International Journal of Radiation Oncology, Biology, Physics 37(5): 975-984, 1997.
  49. Lewis JJ, Leung D, Woodruff JM, et al.: Retroperitoneal soft-tissue sarcoma: analysis of 500 patients treated and followed at a single institution. Annals of Surgery 228(3): 355-365, 1998.
  50. Lopes, JM, Hannisdal, E, Bjerkehagen, B, et al. Synovial sarcoma. Evaluation of prognosis with emphasis on the study of DNA ploidy and proliferation (PCNA and Ki-67) markers. Anal Cell Pathol 1998; 16:45.
  51. Mankin, HJ, Lange, TA, Spanier, SS. The hazards of biopsy in patients with malignant primary bone and soft-tissue tumors. J Bone Joint Surg [Am] 1982; 64:1121.
  52. Mankin, HJ, Mankin, CJ, Simon, MA. The hazards of the biopsy, revisited. Members of the Musculoskeletal Tumor Society. J Bone Joint Surg Am 1996; 78:656.
  53. Marcove RC, Sheth DS, Healey J, et al.: Limb-sparing surgery for extremity sarcoma. Cancer Investigation 12(5): 497-504, 1994.
  54. May, WA, Gishizky, ML, Lessnick, SL, et al. Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation. Proc Natl Acad Sci U S A 1993; 90:5752.
  55. Mazeron, JJ, Suit, HD. Lymph nodes as sites of metastases from sarcomas of soft tissue. Cancer 1987; 60:1800.
  56. McKenzie, AF. The role of magnetic resonance imaging. When to use it and what to look for. Acta Orthop Scand Suppl 1997; 273:21.
  57. Myhre-Jensen, O, Hogh, J, Ostgaard, SE, et al. Histopathological grading of soft tissue tumours. Prognostic significance in a prospective study of 278 consecutive cases. J Pathol 1991; 163:19.
  58. Nieweg, OE, Pruim, l, van Ginkel, RJ, et al. Fluorine18-flurodeoxyglucose PET imaging of soft-tissue sarcoma. J Nucl Med 1996; 37:257.
  59. Nola, M, Babic, D, Ilic, J, et al. Prognostic parameters for survival of patients with malignant mesenchymal tumors of the uterus. Cancer 1996; 78:2543.
  60. O'Byrne K, Steward WP: The role of adjuvant chemotherapy in the treatment of adult soft tissue sarcomas. Critical Reviews in Oncology/Hematology 27(3): 221-227, 1998.
  61. Panicek, DM, Gatsonis, C, Rosenthal, DI, et al. CT and MR imaging in the local staging of primary malignant musculoskeletal neoplasms: Report of the Radiology Diagnostic Oncology Group. Radiology 1997; 202:237.
  62. Pastel-Levy, C, Bell, DA, Rosenberg, AE, et al. DNA flow cytometry of epithelioid sarcoma. Cancer 1992; 70:2823.
  63. Pidhorecky I, Cheney RT, Kraybill WG, et al.: Gastrointestinal stromal tumors: current diagnosis, biologic behavior, and management. Annals of Surgical Oncology 7(9): 705-712, 2000.
  64. Pisters, PW, Leung, DH, Woodruff, J, et al. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol 1996; 14:1679.
  65. Plaat, BE, Muntinghe, FL, Molenaar, WM, et al. Clinical outcome of patients with previously untreated soft tissue sarcomas in relation to tumor grade, DNA ploidy and karyotype. Int J Cancer 1997; 74:396.
  66. Pollack A, Zagars GK, Goswitz MS, et al.: Preoperative vs. postoperative radiotherapy in the treatment of soft tissue sarcomas: a matter of presentation. International Journal of Radiation Oncology, Biology, Physics 42(3): 563-572, 1998.
  67. Potter, DA, Glenn, J, Kinsella, T, et al. Patterns of recurrence in patients with high grade soft tissue sarcomas. J Clin Oncol 1985; 3:353.
  68. Putnam JB Jr, Roth JA: Surgical treatment for pulmonary metastases from sarcoma. Hematology/Oncology Clinics of North America 9(4): 869-887, 1995.
  69. Rooser, B, Berg, NO, Ranstam, J, et al. Prediction of survival in patients with high-grade soft tissue sarcoma. Int Orthop 1990; 14:199.
  70. Rydholm, A, Berg, NO, Gullberg, B, et al. Epidemiology of soft-tissue sarcoma in the locomotor system. A retrospective population-based study of the inter-relationships between clinical and morphologic variables. Acta Pathol Microbiol Immunol Scand [A] 1984; 92:363.
  71. Rydholm, A, Berg, NO, Gullberg, B, et al. Prognosis for soft-tissue sarcoma in the locomotor system. A retrospective population-based follow-up study of 237 patients. Acta Pathol Microbiol Immunol Scand [A] 1984; 92:375.
  72. Santoro A, Tursz T, Mouridsen H, et al.: Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Journal of Clinical Oncology 13(7): 1537-1545, 1995.
  73. Sarcoma Meta-analysis Collaboration: Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Lancet 350(9092): 1647-1654, 1997.
  74. Schmidt RA, Conrad EU III, Collins C, et al.: Measurement and prediction of the short-term response of soft tissue sarcomas to chemotherapy. Cancer 72(9): 2593-2601, 1993.
  75. Schulte, M, Brecht-Krauss, D, Werner, M, et al. Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET. J Nucl Med 1999; 40:1637.
  76. Schwarzbach, MH, Dimitrakopoulou-Strauss, A, Willeke, F, et al. Clinical value of [18-F]] fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas. Ann Surg 2000; 231:380.
  77. Serpell, JW, Pitcher, ME. Pre-operative core biopsy of soft-tissue tumours facilitates their surgical management. Aust N Z J Surg 1998; 68:345.
  78. Soft tissue sarcoma. In: American Joint Committee on Cancer: AJCC Cancer Staging Manual, 5th ed, Lippincott-Raven, Philadelphia, 1997, p.149.
  79. Spiro, IJ, Gebhardt, MC, Jennings, LC, et al. Prognostic factors for local control of sarcomas of the soft tissues managed by radiation and surgery. Semin Oncol 1997; 24:540.
  80. Suit, HD, Rosenberg, AE, Harmon, DC, et al. Soft Tissue Sarcomas. Treatment of Cancer, 3rd Edition. P. Price, K.Sikora (Eds). Chapman & Hall Medical, London, England. 1995, p 805.
  81. Taubert, H, Meye, A, Wurl, P. Prognosis is correlated with p53 mutation type for soft tissue sarcoma patients. Cancer Res 1996; 56:4134.
  82. Temple WJ, Temple CL, Arthur K, et al.: Prospective cohort study of neoadjuvant treatment in conservative surgery of soft tissue sarcomas. Annals of Surgical Oncology 4(7): 586-590, 1997.
  83. Trovik, CS, Bauer, HC, Brosjo, O, et al. Fine needle aspiration (FNA) cytology in the diagnosis of recurrent soft tissue sarcoma. Cytopathology 1998; 9:320.
  84. Ueda, T, Aozasa, K, Tsujimoto, M, et al. Prognostic significance of Ki-67 reactivity in soft tissue sarcomas. Cancer 1989; 63:1607.
  85. Valle AA, Kraybill WG: Management of soft tissue sarcomas of the extremity in adults. Journal of Surgical Oncology 63(4): 271-279, 1996.
  86. van Geel AN, Pastorino U, Jauch KW, et al.: Surgical treatment of lung metastases: the European Organization for Research and Treatment of Cancer - Soft Tissue and Bone Sarcoma Group study of 255 patients. Cancer 77(4): 675-682, 1996.
  87. Van Oosterom AT, Judson I, Verweij J, et al.: STI 157, an active drug in metastatic gastro intestinal stromal tumors (GIST), an EORTC phase I study. Proceedings of the American Society of Clinical Oncology 20: A-2, 1a, 2001.
  88. Van Unnik, JA, Coindre, JM, Contesso, G, et al. Grading of soft tissue sarcomas: Experience of the EORTC soft tissue and bone sarcoma group. Eur J Cancer 1993; 29A:2089.
  89. Vraa S, Keller J, Nielsen OS, et al.: Prognostic factors in soft tissue sarcomas: the Aarhus experience. European Journal of Cancer 34(12): 1876-1882, 1998.
  90. Watson DI, Coventry BJ, Langlois SL, et al.: Soft-tissue sarcoma of the extremity: experience with limb-sparing surgery. Medical Journal of Australia 160(7): 412-416, 1994.
  91. Williard WC, Collin C, Casper ES, et al.: The changing role of amputation for soft tissue sarcoma of the extremity in adults. Surgery, Gynecology and Obstetrics 175(5): 389-396, 1992.
  92. Wunder, JS, Healey, JH, Davis, AM, Brennan, MF. A comparison of staging systems for localized extremity soft tissue sarcoma. Cancer 2000; 88:2721.
  93. Wurl, P, Meye, A, Schmidt H, et al. High prognostic significance of Mdm2/p53 co-overexpression in soft tissue sarcomas of the extremities. Oncogene 1998; 16:1183.
  94. Wurl, P, Taubert, H, Meye, A, et al. Prognostic value of immunohistochemistry for p53 in primary soft-tissue sarcomas: a multivariate analysis of five antibodies. J Cancer Res Clin Oncol 1997; 123:502.
  95. Yang JC, Chang AE, Baker AR, et al.: Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. Journal of Clinical Oncology 16(1): 197-203, 1998.
  96. Yang, RS, Lane, JM, Eilber, FR, et al. High grade soft tissue sarcoma of the flexor fossa. Size rather than compartmental status determine prognosis. Cancer 1995; 76:1398.
  97. Zalupski M, Metch B, Balcerzak S, et al.: Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group Study. Journal of the National Cancer Institute 83(13): 920-926, 1991.
  98. Zalupski MM, Southwest Oncology Group: Phase II Pilot Study of Neoadjuvant Therapy with DOX/DTIC/IFF for Poor-Prognosis Soft Tissue Sarcoma (Summary Last Modified 08/98), SWOG-9119, clinical trial, closed, 06/15/1998